Navigation Links
Updated Phase 2 Data With Flutemetamol Published in Annals of Neurology
Date:9/8/2010

hibits equivalent brain uptake to that of its parent molecule, 11C-Pittsburgh compound B, while also providing high test-retest replicability and potentially greater accessibility for clinical and research use," said Rik Vandenberghe, MD, PhD, Neurology Department, University Hospitals Leuven, Belgium.

"The importance of this study is underscored by the fact that it represents the first direct comparison of 11C-Pittsburgh compound B (which is also known as PiB) to a true analog of this compound," commented William E. Klunk, MD, PhD, professor of Psychiatry and Neurology at the University of Pittsburgh. The current study shows that, in addition to providing equivalent efficacy, flutemetamol actually offers greater test-retest reliability than has been reported with PiB. Flutemetamol thus appears to be a viable and practical alternative to PiB."

The study was also the subject of Dr. Bill Jagust's editorial in the same issue of the Annals of Neurology, which provides further analysis of the study.

The ongoing flutemetamol phase 3 trial program is a series of multicenter studies that include patients who consent to brain biopsy or to post-mortem assays to determine the level of association between imaging detection of amyloid and histopathology findings. A separate study is underway in patients with MCI who may progress to AD. The trials have already commenced with recruitment and imaging of patients at multiple sites in the USA and Europe.

About GE Healthcare

GE Healthcare provides transformational medical technologies and services that are shaping a new age of patient care. Our broad expertise in medical imaging and information technologies, medical diagnostics, patient monitoring systems, drug discovery, biopharmaceutical manufacturing technologies, performance improvement and performance solutions services help our customers to deliver better care to more people around the world at a lower cost. In addition, we part
'/>"/>

SOURCE GE Healthcare
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Poniard Pharmaceuticals to Present Updated Results of Picoplatin Phase 2 Small Cell Lung Cancer Trial at 12th World Conference on Lung Cancer
2. Poniard Pharmaceuticals Announces Updated Results of Picoplatin Phase 2 Trial Demonstrating Survival Benefit in Small Cell Lung Cancer Patients
3. ASCO and ASH Release Updated Guideline on the Use of Chemotherapy-Related Anemia Treatments in Cancer Patients
4. Updated Phase 1 Data for Exelixis XL184 Demonstrate Pharmacodynamic and Clinical Anti-Tumor Activity
5. IDM Pharma Announces Updated Phase 3 Mifamurtide (L-MTP-PE) Data Confirms Statistically Superior Overall Survival in Osteosarcoma Patients
6. IDM Pharma Announces IDM-2101 Updated Phase 2 Results Show Treatment Well Tolerated With Positive Survival Trend in Lung Cancer Patients
7. IDM Pharma Announces Updated Phase 2 UVIDEM(R) Results Showing Durable Disease Control and Tolerability in Advanced Melanoma Patients
8. Kosan Presents Updated Data on Hsp90 Inhibitor, Tanespimycin, in Multiple Myeloma at Ash
9. ORTHO EVRA(R) Prescribing Information Updated
10. VIA Pharmaceuticals Announces Updated DSMB Safety Results for VIA-2291 Ongoing Phase 2 Clinical Program
11. IDM Pharma Announces Updated Data From Mifamurtide (L-MTP-PE) Compassionate Access Program
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... , Jan. 15, 2014 ... research report is available in its ... Markets and Technologies for Advanced Drug ... of Administration ...
(Date:1/15/2014)... 15, 2014  A novel wearable injector slightly larger than an ... patients to self-inject prescription drugs in the large doses required ... diseases, autoimmune deficiencies, and genetic disorders.  An ... by 2018, according to analysts.   Many of these drugs will ...
(Date:1/14/2014)... Texas , Jan. 14, 2014  Luminex Corporation (Nasdaq: ... results for the fourth quarter of 2013 on Monday, February ... for release after the close of trading. ... conference call to discuss the operating highlights and financial results ...
Breaking Medicine Technology:Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 2Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 3Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 4Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 5Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 6Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 7Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 8Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 9Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 10Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 11Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 12Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 13Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 14Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 15Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 16Enable Injections Presents A New Class of Injectors for Drug Delivery at PEPTalk, Drug Delivery Partnership Meetings 2Luminex Corporation Fourth Quarter Earnings Release Scheduled for February 3, 2014 2Luminex Corporation Fourth Quarter Earnings Release Scheduled for February 3, 2014 3
(Date:4/23/2014)... endogenous neural precursor cells cannot alone compensate for ... perspective of neural plasticity, Dr. Yun Xiang and ... the effects of functional electrical stimulation treatment on ... basic fibroblast growth factor and epidermal growth factor ... The researchers found that functional electrical stimulation can ...
(Date:4/22/2014)... industry leaders visited the New Jersey Institute of ... S. Bloom for the launch of the New ... provides a new model for business innovation through ... assets and investment. U.S. Senator Cory Booker, Panasonic ... Taylor, New Jersey Lieutenant Governor Kim Guadagno, New ...
(Date:4/22/2014)... Health clinics that can provide primary care for ... both hospitals and insurance companies while improving patient ... hospital admissions suggests that health clinics that avoid ... save money by lowering hospital admission rates and ... of economics, Penn State Altoona. , The ...
(Date:4/22/2014)... among women using a newer method of planned sterilization ... over a 10-year period than using the more commonly ... University and UC Davis has found. , Published ... the study found the higher risk of pregnancy with ... Essure. , "This study provides essential information for ...
(Date:4/22/2014)... mice and rabbits, Johns Hopkins scientists have found a ... successfully preventing the development of atherosclerosis, the main cause ... of death among humans. The condition develops when fat ... stiff, narrowed and hardened, greatly reducing their ability to ... brain. , In a series of experiments, described April ...
Breaking Medicine News(10 mins):Health News:Government and industry leaders herald launch of NJIT's New Jersey Innovation Institute 2Health News:Clinics not bogged down by red tape can ease health cost burdens 2Health News:Risk of pregnancy greater with newer method of female sterilization 2Health News:Risk of pregnancy greater with newer method of female sterilization 3Health News:Scientists alter fat metabolism in animals to prevent most common type of heart disease 2Health News:Scientists alter fat metabolism in animals to prevent most common type of heart disease 3Health News:Scientists alter fat metabolism in animals to prevent most common type of heart disease 4
... X-rays allowing, dentists to remineralize affected teeth. ... 3 /PRNewswire/ - Quantum Dental Technologies, a Canadian,diagnostic ... monitors the early onset of tooth decay without ... of invasive and painful procedures,and encourages better oral ...
... climate change places 1.7,billion people - 25% of ... warns,anti-poverty agency ActionAid., WASHINGTON, July 2 ... ActionAid launches a new report, "Cereal,Offenders: How the ... and What,They Can Do to Stop It." Read ...
... 2 Regarding the completely fabricated,item about GO3 ... July 14, 2008,edition of Star magazine, none of ... were contacted by the magazine prior to publication., ... reviewing its legal options and will vigorously pursue ...
... Jr,Washington Wizards Guard and Washington, DC native, will ... July 29 featuring bowling at Lucky Strike in,Chinatown. ... support the,cause, including Brendan Haywood and DeShawn Stevenson, ... Vince Carter, Kevin Durant, and,Chris Bosh. Additionally, Craig ...
... individual patients, study says , , WEDNESDAY, July 2 (HealthDay News) ... cells in the blood of lung cancer patients may make ... the genetic "signature" of particular tumors but to monitor changes ... think this is key to personalized medicine," said Dr. Daniel ...
... sports medicine specialist, John Albright, MD, will join three other physicians ... of Fame inductee. , ... Orlando, Florida (PRWEB) July ... MD, will join three other physicians as a 2008 American ...
Cached Medicine News:Health News:Breakthrough Technology That Will Revolutionize the Treatment of Tooth Decay 2Health News:Breakthrough Technology That Will Revolutionize the Treatment of Tooth Decay 3Health News:ActionAid Challenges G8 on Response to Food Crisis 2Health News:GO3 Statement Regarding Erroneous Coverage in Star Magazine 2Health News:Washington Wizards Guard Roger Mason Jr. to Host Bowling at Lucky Strike to Benefit National Kidney Foundation of the National Capital Area 2Health News:Circulating Tumor Cells Reveal Insights Into Lung Cancers 2Health News:Circulating Tumor Cells Reveal Insights Into Lung Cancers 3Health News:Renowned Iowa Orthopaedic Surgeon, John Albright, MD, Inducted into Sports Medicine Hall of Fame 2Health News:Renowned Iowa Orthopaedic Surgeon, John Albright, MD, Inducted into Sports Medicine Hall of Fame 3
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
Medicine Products: